These findings are supported by an analysis of three patient database sets, demonstrating that high expression of BRD4 that can be observed across multiple subtypes of breast cancer is correlated with overall lower recurrence-free survival when compared to patients with low BRD4 expression levels (71). This evidence concerns the gene BRD4 and breast carcinoma.